In fiscal year 2010, we published a negative study examining the association of sorafenib hand-foot syndrome and sorafenib concentration in sweat. We also published our clinical dermatologic findings from following multiple sorafenib patients. Patients on other investigational therapeutics are being evaluated dermatologically at baseline and while on treatment. In addition to thorough clinical evaluations, subjects may undergo skin biopsies and medical photography. As a result of these evaluations, we published a clinical report on cutaneous pigmentation associated with vandetanib (ZD6474). We collaborated with the primary oncology services to report this previously unpublished cutaneous toxicity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC010940-03
Application #
8157538
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
3
Fiscal Year
2010
Total Cost
$16,672
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
O'Sullivan Coyne, Geraldine; Woodring, Therese S; Lee, Chyi-Chia R et al. (2018) Hidradenitis Suppurativa-Like Lesions Associated with Pharmacologic Inhibition of Gamma-Secretase. J Invest Dermatol 138:979-981
Pichard, Dominique C; Cardones, Adela R; Chu, Emily Y et al. (2016) Sorafenib-Induced Eruption Mimicking Erythema Multiforme. JAMA Dermatol 152:227-8
Brooks, Sara; Linehan, W Marston; Srinivasan, Ramaprasad et al. (2011) Successful laser treatment of vandetanib-associated cutaneous pigmentation. Arch Dermatol 147:364-5
Jain, Lokesh; Gardner, Erin R; Figg, William D et al. (2010) Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction. Pharmacotherapy 30:52-6
Azad, Nilofer S; Aragon-Ching, Jeanny B; Kong, Heidi H (2009) Clin Cancer Res 15:7749
Azad, Nilofer S; Aragon-Ching, Jeanny B; Dahut, William L et al. (2009) Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 15:1411-6
Kong, Heidi H; Turner, Maria L (2009) Array of cutaneous adverse effects associated with sorafenib. J Am Acad Dermatol 61:360-1
Kong, Heidi H; Fine, Howard A; Stern, Jere B et al. (2009) Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. Arch Dermatol 145:923-5
Lacouture, Mario E; Wu, Shenhong; Robert, Caroline et al. (2008) Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13:1001-11
Kong, Heidi H; Sibaud, Vincent; Chanco Turner, Maria L et al. (2008) Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol 144:820-2